vos-headline-type-email-header-062620
Featured

Addressing Assessment and Access Issues for Rare Diseases

With the promise of more rare disease treatments on the horizon (particularly genetic treatments for hemophilia and sickle cell disease, which promise to be “one and done” therapies), their much higher per patient cost will create market access and other challenges to payers, providers, and patients.

ISSUE HIGHLIGHTS

COLUMNS

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×